参考文献/References:
[1] Biedermann L,Rogler G.The intestinal microbiota:its role in health and disease[J].Eur J Pediatr,2015,174(2):151-167.
[2] Eckburg PB,Bik EM,Bernstein CN,et al.Diversity of the human intestinal microbial flora[J]. Science,2005,308(5728):1635-1638.
[3] Nuding S,Antoni L,Stange EF.The host and the flora[J].Dig Dis,2013,31(3-4):286-292.
[4] Sargent J.Obesity:rethinking inflammation and adipocyte homeostasis[J].Nat Rev Endocrinol,2014,10(8):446.
[5] van GreevenbroekMM,Schalkwijk CG,Stehouwer CD.Obesity-associated low-grade inflammation in type 2 diabetes mellitus:causes and consequences[J].Neth J Med,2013,71(4):174-187.
[6] El Kaoutari A,Armougom F,Gordon JI,et al.The abundance and variety of carbohydrate-active enzymesin the human gut microbiota[J].Nat Rev Microbiol,2013,11(7):497-504.
[7] Tang C,Ahmed K,Gille A,et al.Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes[J].Nat Med,2015,21(2):173-177.
[8] Kimura I,Ozawa K,Inoue D,et al.The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43[J].Nat Commun,2013,4:1829.
[9] Kasai C,Sugimoto K,Moritani I,et al.Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population,as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing[J].BMC Gastroenterol,2015,15:100.
[10] 彭喜春,黄嘉成.肠道梭菌在机体能量过度摄入中的作用[J].现代食品科技,2014,3:262-265.
[11] Jihad B,Raymond F,Julnar M,et al.Obesity as a risk factor for clostridium difficile infection[J].Clin Infect Dis,2013,57(4):489-493.
[12] Wang H,Eckel RH.Lipoprotein lipase:from gene to obesity[J].Am J Physiol Endocrinol Metab,2009,297(2):E271-288.
[13] Kotzbeck P,Zechner R.Angiopoietin-like 4:an endogenous break of intestinal lipid digestion[J].Mol Metab,2014,3(2):88-89.
[14] Backhed F, Manchester JK, Semenkovich CF,et al.Mechanisms underlying the resistance to diet-induced obesity in germ-free mice[J].Proc Natl Acad Sci USA,2007,104(3):979-984.
[15] 傅娟,谷翔.游离脂肪酸与冠心病之间的关系及发展[J].医药前沿,2012,27:149-150.
[16] Jaimes A,Ping H,Runxia T,et al.Human glomerular endothelium:interplay among glucose,free fatty acids,angiotensin Ⅱ,and oxidative stress[J].Am J Physiol Renal Physiol,2010,298(1):F125-F132.
[17] Zeneng W,Klipfell E,Bennett BJ,et al.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J]. Nature,2011,472(7341):57-63.
[18] Vaishnavi C.Translocation of gut flora and its role in sepsis[J].Indian J Med Microbiol,2013,31(4):334-342.
[19] Wright SD,Ramos RA,Tobias PS,et al.CD14,a receptor for complexes of lipopolysaceharide(LPS)and LPS binding protein[J].Science,1990,249(4975):143-1433.
[20] Mahalle N,Garg M,Kulkarni M,et al.Association of inflammatory cytokines with traditional and nontraditional cardiovascular risk factors in Indians with known coronary artery disease[J].Ann Med Health Sci Res,2014,4(5):706-712.
[21] González GE,Rhaleb NE,D'Ambrosio MA,et al.Deletion of interleukin-6 prevents cardiac inflammation,fibrosis and dysfunction without affecting blood pressure in angiotensin Ⅱ-high salt-induced hypertension[J]. J Hypertens,2015,33(1):144-152.
[22] Fedacko J,Singh RB,Gupta A.Inflammatory mediators in chronic heart failure in North India[J].Acta Cardiol,2014,69(4):391-398.
[23] Gedikli O, Dogan A, Altuntas I, et al. Inflammatory markers according to types of atrial fibrillation[J]. Int J Cardiol, 2007,120(2):193-197.
[24] Hussein AA,Gottdiener JS,Bartz TM,et al.Inflammation and sudden cardiac death in a community-based population of older adults:the Cardiovascular Health Study[J].Heart Rhythm,2013,10(10):1425-1432.
[25] Tena D,Losa C,Medina MJ,et al.Peritonitis caused by Bifidobacterium longum:case report and literature review[J].Anaerobe,2014,27:27-30.
[26] Zbinden A,Zbinden R,Berger C,et al.Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy[J]. Neonatology,2014,107(1):56-59.
[27] Sánchez B,González-Rodríguez I,Arboleya S,et al.The effects of Bifidobacterium breve on immune mediators and proteome of HT29 cells monolayers[J].Biol Med Res Int, 2015,2015:479140.
[28] Presti I,D'Orazio G,Labra M,et al.Evaluation of the probiotic properties of new Lactobacillus and Bifidobacterium strains and their in vitro effect[J].Appl Microbiol Biotechnol,2015,99(13):5613-5626.
[29] Llopis M,Antolin M,Carol M,et al.Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa[J].Inflamm Bowel Dis,2009,15(2):275-283.
[30] Alexandre Y,le Berre R,Barbier G,et al.Screening of Lactobacillus spp. for the prevention of Pseudomonas aeruginosa pulmonary infections[J].BMC Microbiol, 2014,14:107.
[31] Seil S,Mary EM,Si C,et al.Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma[J].Respir Res,2014,15:46.
[32] Koulis C,Chen YC,Hausding C,et al.Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice[J].Arterioscler Thromb Vasc Biol,2014,34(3):516-525.
[33] Kawahara T,Takahashi T,Oishi K,et al.Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model[J].Microbiol Immunol,2015,59(1):1-12.
[34] Underwood MA,Arriola J,Gerber CW,et al.Bifidobacterium longum subsp. infantis in experimental necrotizing enterocolitis:alterations in inflammation, innate immune response, and the microbiota[J].Pediatr Res,2014,76(4):326-333.
[35] Ling Z,Liu X,Cheng Y,et al.Clostridium butyricum combined with Bifidobacterium infantis probiotic mixture restores fecal microbiota and attenuates systemic inflammation in mice with antibiotic-associated diarrhea[J].Biomed Res Int,2015,2015:582048.
[36] Wang Y,Xie J,Li Y,et al.Probiotic Lactobacillus casei Zhang reduces pro-inflammatory cytokine production and hepatic inflammation in a rat model of acute liver failure[J].Eur J Nutr,2016,55(2):821-831.
[37] Miyoshi M,Ogawa A,Higurashi S,et al.Anti-obesity effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice[J].Eur J Nutr,2014,53(2):599-606.
[38] Toral M,Gomez-Guzman M,Jimenez R,et al.The probiotic Lactobacillus coryniformis CECT5711 reduces the vascular pro-oxidant and pro-inflammatory status in obese mice[J].Clin Sci(Lond),2014,127(1):33-45.
[39] Novotny Núñez I, Maldonado Galdeano C, de Moreno de LeBlanc A,et al.Lactobacillus casei CRL 431 administration decreases inflammatory cytokines in a diet-induced obese mouse model[J].Nutrition,2015,31(7-8):1000-1007.
[40] Huan W,Jing G,Wenfeng W,et al.Are there any different effects of Bifidobacterium,Lactobacillus and Streptococcus on intestinal sensation,barrier function and intestinal immunity in PI-IBS mouse model?[J]. PLoS One,2014, 9(3):e90153.
[41] Cani PD,Possemiers S,van de Wiele T.Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability[J].Gut,2009,58:1091-1093.
[42] Hercia M,Livia T,Karina S,et al.Effects of probiotics on glycemic control and inflammation in type 2 diabetes mellitus:a randomized,double-blind, placebo-controlled study[J].FASEB J,2015, 29(meeting abstract):9226.
[43] Tripolt NJ,Leber B,Blattl D,et al.Short communication:effect of supplementation with Lactobacillus casei Shirota on insulin sensitivity,β-cell function, and markers of endothelial function and inflammation in subjects with metabolic syndrome—A pilot study[J].J Dairy Sci,2013,96(1):89-95.
[44] Canxia H,Yujuan S,Wei S.Targeting gut microbiota as a possible therapy for diabetes[J].Nutr Res,2015,35(5):361-367.
[45] 赵莹,付军.肠道菌群与心血管疾病的研究进展[J].中国老年学杂志,2014,34(5): 1443-1444.
[46] Rerksuppaphol S,Rerksuppaphol LA.Randomized Double-blind Controlled Trial of Lactobacillus acidophilus plus Bifidobacterium bifidum versus Placebo in Patients with Hypercholesterolemia[J].J Clin Diagn Res,2015,9(3):KC01-04.
[47] Minami J,Kondo S,Yanagisawa N,et al.Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial[J].J Nutr Sci,2015,4:e17.
相似文献/References:
[1]张琪 宋晓鹏 任茂佳 吴广 赵兴胜.氧化三甲胺与心血管疾病的研究新进展[J].心血管病学进展,2020,(1):81.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.022]
ZHANG Qi,SONG Xiaopeng,REN Maojia,et al.Trimethylamine Oxide and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(3):81.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.022]
[2]李靖,任彭,努尔比耶·买买提,等.三甲胺-N-氧化物与冠心病和心力衰竭的研究进展[J].心血管病学进展,2020,(3):272.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.014]
LI Jing,REN Peng,Nuerbiye·Maimaiti,et al.Trimethylamine-N-oxide and Coronary Heart Disease and Heart Failure[J].Advances in Cardiovascular Diseases,2020,(3):272.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.014]
[3]王猛 江洪.肠道菌群及其代谢产物与心房颤动的研究进展[J].心血管病学进展,2022,(3):214.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
WANG Meng,JIANG Hong.Gut Microbiota an d Its Metabolites in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(3):214.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[4].肠-脑轴与心血管疾病的研究进展[J].心血管病学进展,2022,(7):595.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
TAN Wuping,W ANG Meng,ZHOU Xiaoya.Gut-Brain Axis and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(3):595.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[5]刘杏利 高中山 段豪亮 赵奕 马玉兰.肠道菌群及其代谢物与心律失常关系的研究进展[J].心血管病学进展,2022,(11):1002.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.009]
LIU Xingli,GAO Zhongshan,DUAN Haoliang,et al.The Relationship Between Intestinal Flora and Its Metabolites and Arrhythmia[J].Advances in Cardiovascular Diseases,2022,(3):1002.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.009]
[6]张嘉原 张莉.果糖代谢与血脂异常的研究进展[J].心血管病学进展,2022,(12):1114.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.013]
ZHANG Jiayuan ZHANG Li.Fructose Metabolism and DyslipidemiaA Systematic Review[J].Advances in Cardiovascular Diseases,2022,(3):1114.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.013]
[7]卢燕 刘亚萍 罗强 张全波 汪汉.肠道菌群及其代谢物与痛风[J].心血管病学进展,2023,(2):177.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.018]
LU Yan,LIU Yaping,LUO Qiang,et al.Intestinal Flora and Its Metabolites and Gout[J].Advances in Cardiovascular Diseases,2023,(3):177.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.018]
[8]蒋振江 刘富强 王军奎.肠道菌群与肥胖的关系研究进展[J].心血管病学进展,2023,(3):265.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.017]
JIANG Zhenjiang,LIU Fuqiang,WANG Junkui.The Relationship Between Gut Microbiota and Obesity[J].Advances in Cardiovascular Diseases,2023,(3):265.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.017]
[9]李帅 刘富强 王军奎.酒精摄入对肠道菌群的影响及其机制研究进展[J].心血管病学进展,2023,(2):172.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.017]
LI ShuaiLIU FuqiangWANG Junkui.Effects of Alcohol Intake on Intestinal Flora and Its Mechanism[J].Advances in Cardiovascular Diseases,2023,(3):172.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.017]
[10]黄露霈 成泽东.肠道微生物细胞外囊泡对心血管系统影响的研究进展[J].心血管病学进展,2023,(4):355.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.015]
UANG Lupei,CHENG Zedong ?/html>.Research Progress on the Effect of Intestinal Microbial?#160Extracellular Vesicles on Cardiovascular System[J].Advances in Cardiovascular Diseases,2023,(3):355.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.015]